A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results

被引：0
|
作者：
Lakhani, Nehal J.
Hamid, Omid
Brana, Irene
Lostes-Bardaji, M. Julia
Gajate, Pablo
Lopez-Criado, Maria Pilar
Swiecicki, Paul
de Miguel, Maria J.
Gil-Martin, Marta
Moreno, Victor
Muller, Aixa Elena Soyano
Ortiz, Ana Gonzalez
Sun, Dylan
Modi, Dimple
Zheng, Wenjun
Jankovic, Vladimir
Salvati, Mark
Fury, Matthew G.
Cristea, Mihaela C.
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] Angeles Clin & Res Inst, Los Angeles, CA USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Inst Oncol, Barcelona, Spain
[5] Inst Oncol VHIO, Barcelona, Spain
[6] Ramon & Cajal Univ Hosp, Madrid, Spain
[7] Univ Texas MD Anderson Canc Ctr, Madrid, Spain
[8] Univ Michigan, Ann Arbor, MI 48109 USA
[9] START Madrid CIOCC, Madrid, Spain
[10] Inst Catala Oncol IDIBELL, Barcelona, Spain
[11] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain
[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[13] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2650
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF TRANSCON TLR7/8 AGONIST ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES: INITIAL RESULTS FROM DOSE ESCALATION
    Davar, Diwakar
    Aghmesheh, Morteza
    Algazi, Alain
    Bajor, David
    Ganju, Vinod
    Laux, Douglas
    Spira, Alexander
    Ahern, Elizabeth
    Grewal, Jaspreet
    Rand, Jamie
    Sweis, Randy
    Karlsson, Jens-Jakob
    Kriegbaum, Mette
    Wu, Yang
    Tran, Tuan-Anh
    Singel, Stina
    Gabrail, Nashat
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A795 - A795
  • [22] A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors
    Goel, Sanjay
    Ulahannan, Susanna Varkey
    Olszanski, Anthony J.
    LoRusso, Patricia
    Sanborn, Rachel E.
    Sharma, Sunil
    Emens, Leisha A.
    Reilley, Matthew
    Priego, Victor
    Li, Shuli
    Wang, Bingxia
    Dong, Lixian
    Sachsenmeier, Kris
    Gibbs, John
    Gharavi, Robert
    Martinez, Alonzo
    Proscurshim, Igor
    Fram, Robert J.
    Gomez-Pinillos, Alejandro
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [24] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
  • [25] Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    Freyer, G.
    Isambert, N.
    You, B.
    Zanetta, S.
    Falandry, C.
    Favier, L.
    Trillet-Lenoir, V.
    Assadourian, S.
    Soussan-Lazard, K.
    Ziti-Ljajic, S.
    Fumoleau, P.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 598 - 603
  • [26] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
  • [27] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
  • [28] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [29] Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    G Freyer
    N Isambert
    B You
    S Zanetta
    C Falandry
    L Favier
    V Trillet-Lenoir
    S Assadourian
    K Soussan-Lazard
    S Ziti-Ljajic
    P Fumoleau
    British Journal of Cancer, 2012, 107 : 598 - 603
  • [30] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Infante, Jeffrey R.
    Cohen, Roger B.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 576 - 588
12345